Codexis, Inc.

Fornia Biosolutions, Inc.

Crosswalk Therapeutics, Inc.

Fomia Biosolutions, Inc.

Fornia Biosoultions, Inc.

Xiyun Zhang

Gjalt W Huisman

Jie Yang

Nicholas John Agard

Vesna Mitchell

Benjamin Mijts

Goutami Banerjee

Jonathan Vroom

Robert Osborne

Erika M Milczek

Jeffrey C Moore

Khin Oo

Ish Kumar Dhawan

Khin Yu Naing Htwe

Gregory Miller

Jovana Nazor

Christopher K Savile

Rama Voladri

David Elgart

Dipnath Baidyaroy

Yingxin Zhang

Eric Lin Hu

Derek J Smith

Jack S Liang

Michael D Clay

David Entwistle

Attila Andor

Tatsuya Fukushima

Louis Clark

Lisa Marie Newman

Melissa Ann Mayo

Stephan Jenne

Mathew G Miller

Wenhua Lu

Imad N Sawaya

Jun Zhu

Steven James Collier

Shiwei Song

Birgit Kosjek

Yong Koy Bong

Ravi David Garcia

Michael Vogel

Shane Grosser

Matthew Truppo

Ryan Fong

Sally Rhiannon Postlethwaite

Donald Scott Baskerville

Ezhilkani Subbian

Russell Javiniar Sarmiento

Marielle De Jesus Palatino

Jijiao Zeng

Jian Ding

Andrew Shaw

Nikki Dellas

John M Gruber

Anupam Gohel

James Joseph LaLonde

Jagadeesh Mavinahalli

Kripa Rao

John H Grate

Roger Arthur Sheldon

Chris Edano Noriega

Sheela Muley

Christopher Michael Micklitsch

Antoinette Sero

John D Munger, Jr

Jeffrey Colbeck

Sachin Patil

William Buchanan Porterfield

Brent Dorr

Douglas E Fuerst

Stephen Joshua Macaso Millet

Jed Lee Hubbs

Jungjoo Yoon

Oscar Alvizo

Wei Zhang

Robert G McDaniel

James Nicholas Riggins

Ellen D Eberhard

Ee Lui Ang

Catherine M Cho

Galit Meshulam-Simon

Derek Smith

Jing Tian

Khin Yu Htwe

Gjait W Huisman

The present disclosure provides engineered transaminase enzymes having improved properties as compared to a naturally occurring wild-type transaminase enzyme. Also provided are polynucleotides encoding the engineered transaminase enzymes, host cells capable of expressing the engineered transaminase enzymes, and methods of using the engineered transaminase enzymes to synthesize a variety of chiral compounds.

Transaminase polypeptides

The present disclosure relates to engineered penicillin G acylase (PGA) enzymes having improved properties, polynucleotides encoding such enzymes, compositions including the enzymes, and methods of using the enzymes.

Penicillin-G acylases

The disclosure relates to engineered enone reductase polypeptides having improved properties, polynucleotides encoding the engineered polypeptides, related vectors, host cells, and methods for making the engineered enone reductase polypeptides. The disclosure also provides methods of using the engineered enone reductase polypeptides for chemical transformations.

Enone reductases

The present invention provides improved P450-BM3 variants with improved activity. In some embodiments, the P450-BM3 variants exhibit improved activity over a wide range of substrates.

P450-BM3 variants with improved activity

The present invention provides engineered carboxyesterase enzymes having improved properties as compared to a naturally occurring wild-type carboxyesterase enzymes, as well as polynucleotides encoding the engineered carboxyesterase enzymes, host cells capable of expressing the engineered carboxyesterase enzymes, and methods of using the engineered carboxyesterase enzymes in amidation reactions.

Carboxyesterase polypeptides for amide coupling

The present invention provides engineered proline hydroxylase polypeptides for the production of hydroxylated compounds, polynucleotides encoding the engineered proline hydroxylases, host cells capable of expressing the engineered proline hydroxylases, and methods of using the engineered proline hydroxylases to prepare compounds useful in the production of active pharmaceutical agents.

Engineered proline hydroxylase biocatalysts for hydroxylation of chemical compounds

The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved stability under both acidic (pH<4.5) and basic (pH>7) conditions. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.

Human alpha-galactosidase variants

The present invention relates to variant xylanase enzymes and their use thereof.

Xylanase variants and methods

The invention is directed to novel variant endoglucanases and their use thereof.

Additional endoglucanase variants and methods

The present invention provides engineered phenylalanine ammonia-lyase (PAL) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered phenylalanine ammonia-lyase (PAL) polypeptides.

Engineered phenylalanine ammonia lyase polypeptides

Vectors for expression of biocatalysts

Growing community of inventors

Fremont, CA, United States of America

Xiyun Zhang